Tatva Chintan Pharma Chem Limited (TATVA) Fair Value & Analysis
Basic Materials · IN · Market cap ₹37.8B (≈ $401M) · ISIN INE0GK401011
What is Tatva Chintan Pharma Chem Limited really worth?
Below-average quality, and trading another 499% above our fair value of ₹280.48.
As of Aug 27, 2026, the fair value of Tatva Chintan Pharma Chem Limited is ₹280.48 per share against a price of ₹1,679, so the fair value sits 83% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Aug 27, 2026
From 14 valuation models · updated 10 days ago
Share price −2.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹364.63). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range ₹637.12 – ₹2,865 · fair‑value band ₹229.22 – ₹364.63 · the ₹1,679 price screens above the ₹280.48 fair value. Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Tatva Chintan Pharma Chem Limited (TATVA) currently trades at ₹1,679, while our model-based Fair Value estimate is ₹280.48, implying the stock looks roughly 498.8% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Basic Materials sector. Bull case: the Multiples group reads highest at a median of ₹305.62 per share, and 0 of the 14 models we run sit above the ₹1,679 price. Bear case: the Earnings-Based group reads lowest at ₹123.69, and 14 of the 14 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Tatva Chintan Pharma Chem Limited generated revenue of ₹5.6B at a net margin of 9.2%. Revenue grew 42.9% year over year. It earns a return on equity of 5.5%. Net debt stands at ₹1.1B. Fundamentals as of Aug 27, 2026
Our scenario range runs from ₹229.22 (bear case) to ₹364.63 (bull case); at ₹1,679, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high and 72% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at −58% fair-value upside, at −83%, TATVA screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹9.57 per share, which is 3.9 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 14 models by family
Widest divergence: Multiples (₹305.62) versus Earnings-Based (₹123.69). Highest evidence: Residual Income (76).
Notify me when TATVA reaches fair value
Put TATVA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 86
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Tatva Chintan Pharma Chem Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor and zinc ion batteries; and pharmaceutical and agrochemical products, and other specialty chemicals …
Full company description
Tatva Chintan Pharma Chem Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor and zinc ion batteries; and pharmaceutical and agrochemical products, and other specialty chemicals in the form of intermediates, disinfectants, catalysts, and solvents. The company serves automotive, refinery, pharmaceutical, agro-chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrances industries. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Tatva Chintan Pharma Chem Limited reported revenue of ₹5.1B in FY2026 versus ₹4.3B in FY2022, a compound +4.1%/yr. Reported net income was ₹421M in FY2026, compounding −18.6%/yr from FY2022.
TATVA screens 499% overvalued. Compare with Linde plc →
Peer Group
Specialty Chemicals · 695 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $485.35 | $222.03 | −54% |
| The Sherwin-Williams Company SHW | $344.86 | $143.38 | −58% |
| Ecolab Inc ECL | $286.75 | $96.18 | −66% |
| Air Products and Chemicals, Inc APD | $308.09 | $122.14 | −60% |
| Givaudan SA GIVN | CHF 3,282 | CHF 1,498 | −54% |
| Wanhua Chemical Group 600309 | ¥77.66 | ¥68.03 | −12% |
| 500820 500820 | ₹2,757 | ₹557.43 | −80% |
| Novozymes A/S NSISB | kr 456.40 | kr 169.99 | −63% |
| Asian Paints Limited ASIANPAINT | ₹2,630 | ₹696.23 | −74% |
| PPG Industries, Inc PPG | $114.22 | $71.31 | −38% |
Compare Tatva Chintan Pharma Chem Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Tatva Chintan Pharma Chem Limited (TATVA) overvalued or undervalued?
What is the fair value of TATVA?
What is the quality score of TATVA?
What is the price target for Tatva Chintan Pharma Chem Limited (TATVA)?
What is the Tatva Chintan Pharma Chem Limited stock forecast for 2026?
What is the revenue of Tatva Chintan Pharma Chem Limited (TATVA)?
What is the net profit margin of TATVA?
Does Tatva Chintan Pharma Chem Limited pay a dividend?
Watch Tatva Chintan Pharma Chem Limited in the live analysis
One click puts Tatva Chintan Pharma Chem Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.